EXSIGHT VENTURES
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis

Congratulations to lensgen team on this significant milestone: IDE Approval from the U.S. FDA to Begin Clinical Study

11/30/2021

1 Comment

 
Picture
Great news for LensGen, Inc. The approval of their IDE will allow the company to begin their pivotal trial with the ultimate goal of seeking premarket approval. Congratulations to Ram and the team! Their persistence and dedication is inspiring. ​
LensGen, Inc., a privately held ophthalmic medical device company, announced today that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the company's Juvene intraocular lens (IOL) for patients with cataracts.
The LensGen Juvene IOL is designed to permanently restore clear and continuous vision at all distances including near and intermediate. The lens is modular and has a fluid optic component that changes shape to adjust focus on demand for today's active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a broad range of lighting conditions. The lens is implanted using the same surgical techniques used with traditional intraocular lenses.  Full press release.    

Watch LensGen's Panel Discussion at ASCRS in Las Vegas Last August
1 Comment
Tom Boyd
12/2/2021 09:05:09 am

Fantastic!

Reply



Leave a Reply.

    Author

    ExSight Ventures

    Archives

    July 2021
    June 2021
    March 2021
    January 2021
    December 2020
    August 2020
    July 2020
    June 2020
    February 2020
    December 2019
    October 2019
    August 2019
    July 2019
    February 2019
    September 2018
    August 2018
    July 2018

    View my profile on LinkedIn

    Categories

    All

    RSS Feed

 ©ExSight Ventures, LLC                    Privacy Policy                    Terms and Conditions          Disclaimer       
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis